tetano
Editor, Senior Moderator
SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the initiation of a Phase 2 clinical study of TCN-032 in a viral challenge model. TCN-032 is a broadly protective and fully human monoclonal antibody being developed for the treatment of influenza A infections.
..
http://eon.businesswire.com/news/eo...ne-Sciences-Initiates-Phase-2-Viral-Challenge
..
http://eon.businesswire.com/news/eo...ne-Sciences-Initiates-Phase-2-Viral-Challenge